ENHERTU plus Pertuzumab granted breakthrough therapy designation in the U.S. as first-line therapy for patients...

FDA advisors spurn GSK’s Blenrep comeback dreams on safety, trial concerns

Nature Medicine published Phase 1 results of Innovent Biologics’ anti-CLDN18.2 ADC (IBI343) in patients with...

Oncomatryx Biopharma awarded prestigious EIC accelerator funding to advance groundbreaking ADCs

Defence’s Accum technology With ADC And radiopharmaceutical programs target cancer

Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova for up to $951M